Frontlight ResearchEarly access
Taking peoplePhase 3
Leflunomide for polymyalgia rheumatica during steroid dose reduction
Tests leflunomide against placebo for preventing relapses in people with polymyalgia rheumatica.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Netherlands2 sites in 1 countryChoose a country to see its sites
- Registry title
- Treatment with leflunomide in patients with polymyalgia rheumatica
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 94 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 1 Apr 2028
- Type of study
- Interventional
- Record updated
- 12 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 or older with newly diagnosed polymyalgia rheumatica (PMR). It tests whether leflunomide can prevent flare-ups while steroid doses are lowered.
- Age
- 50 years or older
- Sex
- Women and men
- Disease stage
- Newly diagnosed PMR, meeting the ACR/EULAR 2012 PMR classification criteria.
- Earlier treatment
- Must have been on corticosteroids (glucocorticoids) for less than 4 weeks. Cannot join if on glucocorticoids for more than 4 weeks or more than 25 mg/day, or if treated with DMARD/biological drugs in the last 5 years.
Main reasons for not taking part
- Other connective tissue disease, including vasculitis or giant-cell arteritis
- Active infection, hepatitis B or C, or HIV
- Cancer within the past 5 years, except nonmelanoma skin cancer
- Transplanted organ (except a corneal transplant more than 3 months before screening)
- Kidney or liver problems, anemia, low blood cell counts, or poorly controlled high blood pressure
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Female or male aged ≥ 50 years 2. PMR according to the ACR/EULAR 2012 PMR core (essential) classification criteria 3. Newly diagnosed PMR being on corticosteroids glucocorticoids for less than 4 weeks
Who cannot take part
- Presence of any other connective tissue disease, including vasculitis/giant-cell arteritis 2. PMR on glucocorticoidsglucocorticosteroids for >4 week or >25 mg/day 3. History of alcohol or drug abuse or current alcohol or drug abuse 4. Transplanted organ (except corneal transplant performed more than 3 months prior to screening) 5. Evidence (as assessed by the investigator) of active infection, presence of hepatitis B surface antigen or hepatitis C antibody in blood, HIV positivity. 6. Malignancy within 5 years prior to screening, except for nonmelanoma skin cancer 7. Exposure to DMARD/biological in the last 5 years 8. Pain syndromes, e.g. fibromyalgia, drug-induced myalgia 9. Active thyroid disease 10. Neurological diseases, e.g. Parkinson's disease 11. Contraindications for leflunomide 12. Laboratory abnormalities: renal or hepatic impairment, anemia and significant cytopenia 13. Uncontrolled or poorly controlled hypertension 14. Major surgery or hospitalization within 3 month prior to screening
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate whether the use of leflunomide can prevent relapses during corticosteroid tapering in patients with polymyalgia rheumatica
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Leflunomide in PMR; A multicenter randomized placebo controlled treatment study of Leflunomide in polymyalgia rheumatica
- Plain-language title
- Leflunomide for polymyalgia rheumatica during steroid dose reductionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 12 August 2024